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Background: The differential diagnosis of a neonate or fetus presenting with a bell-shaped or long narrow thorax
includes a wide range of bony dysplasia syndromes. Where this is accompanied by respiratory distress, asphyxiating
thoracic dystrophy (ATD, Jeune syndrome) is an important potential diagnosis. Shwachman-Diamond syndrome
(SDS) is widely recognised as a cause of exocrine pancreatic dysfunction, short stature and bone marrow failure. It is
not so well appreciated that rib and/or thoracic cage abnormalities occur in 30–50% of patients and that, in severe
cases, these abnormalities may lead to thoracic dystrophy and respiratory failure in the newborn. There are,
however, at least three previous case reports of children who were initially diagnosed with ATD who were
subsequently shown to have SDS.
Case presentation: This report details the case history of a patient misdiagnosed as having ATD as a neonate
following the neonatal asphyxial death of her brother. She subsequently developed progressive pancytopenia but was
only diagnosed with SDS at 11 years of age after referral for haematopoietic stem cell transplantation for bone marrow
failure accompanied by trilineage dysplasia and clonal cytogenetic abnormalities on bone marrow examination.
Subsequent testing revealed the presence of fat globules in stools, reduced faecal chymotrypsin, fat-soluble vitamin
deficiency, metaphyseal dysplasia on skeletal survey and heterozygous mutations of the SBDS gene.
Conclusion: This report highlights the potential for diagnostic confusion between ATD and SDS. It is important to
include SDS in the differential diagnosis of newborns with thoracic dystrophy and to seek expert clinical and
radiological assessment of such children.
Keywords: Shwachman-Diamond syndrome, Asphyxiating thoracic dystrophy, Jeune syndrome, Differential
diagnosis, Haematopoietic stem cell transplantation, Isochromosome 7q, Pancreatic insufficiency, Neonatal respiratory
distressBackground
The presentation of a bell-shaped or long narrow thorax is
often associated with short limbs and sometimes polydac-
tyly. The differential diagnosis for this presentation is wide
and includes asphyxiating thoracic dystrophy (ATD, Jeune
syndrome, OMIM 208500), Ellis-van Creveld syndrome,
short rib-polydactyly syndrome (types I-IV), thoracolaryn-
gopelvic dysplasia (Barnes syndrome) and Shwachman-* Correspondence: colin.steward@uhbristol.nhs.uk
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we have concentrated solely on the risk of diagnostic
confusion between ATD and SDS.
ATD was first described by Jeune et al. in a pair of sib-
lings in 1955 [1]. It is an autosomal recessive disorder char-
acterised by chondrodysplasia and multiple organ
involvement [2] with an incidence of one case per 100,000
to 130,000 live births [3]. Diagnosis in the prenatal or neo-
natal period is based on clinical and radiological findings.
Two causative genes have recently been identified, IFT80 at
3q24-q26 [4] and DYNC2H1 at 11q14.3-q23.1 [5], and sev-
eral loci have been implicated in those lacking mutations of
these genes.is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
properly cited.
Figure 1 Babygram of the affected male sibling with severe
respiratory distress. There is mild platyspondyly and generalised
shortening of ribs and long bones. The metaphyses of the long
bones are slightly irregular and there is some metaphyseal sclerosis.
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disproportionately short limbs. All patients have small
chests but the clinical phenotype varies widely, with
some children dying in the neonatal period from as-
phyxia but others having milder respiratory symptoms.
Patients are increasingly surviving the neonatal period
due to better intensive care therapies, which in turn
allow them to reach an age where there is decreased reli-
ance on chest wall mechanics for ventilation [2,6]. As a
result, while patients in the past rarely survived child-
hood, some are now living to adulthood where they often
display chronic renal failure and other manifestations of
the syndrome. Extraosseous manifestations particularly
affect the kidney, liver and pancreas. Hepatic fibrosis and
pancreatic cystic disease and fibrosis have all been well
described [7].
SDS is an autosomal recessive disorder characterised pri-
marily by exocrine pancreatic dysfunction, short stature,
metaphyseal dysplasia and bone marrow failure [8]. The
gene responsible, SBDS at 7q11, was identified in the last
decade [9,10] and mutations are identifiable in over 75% of
patients with the syndrome. Haematological involvement
may cause isolated cytopenias or pancytopenia, and there
is a propensity to develop myelodysplasia (MDS) or acute
myeloid leukaemia [11]. The commonest cytopenia at
diagnosis is neutropenia. This is seen in 88–100% of SDS
patients from neonatal life onwards, although neutrophil
counts can vary from severely low to normal [8]. Imaging
studies show pancreatic lipomatosis [12].
Published case series in SDS [13-15] describe metaphy-
seal chondroplasia in 40-80% of patients and short stature
in more than 50%. Other skeletal abnormalities may in-
clude clinodactyly, kyphosis, scoliosis, coxa vara, vertebral
collapse, slipped femoral epiphysis, supernumerary meta-
tarsals, genu and cubitus valgus, pes cavus and osteopenia.
Rib and/or thoracic cage abnormalities occur in 30-50% of
patients. In severe cases, these abnormalities may lead to
thoracic dystrophy and respiratory failure in the newborn
period [8].
The differential diagnosis of a neonate or fetus presenting
with a bell-shaped or long narrow thorax includes a wide
range of bony dysplasia syndromes. Where this is accom-
panied by respiratory distress, ATD is an important poten-
tial diagnosis. SDS must, however, be considered in this
differential and be excluded by appropriate investigation.
There are historical references to at least three cases of
children initially diagnosed with ATD, who were subse-
quently shown to have SDS [16-19]. This report details the
case history of another patient misdiagnosed as having
ATD as a neonate following the neonatal asphyxial death of
her brother. She was then diagnosed with SDS at 11 years
of age after referral for haematopoietic stem cell transplant-
ation for bone marrow failure. It highlights the potential
for diagnostic confusion between ATD and SDS inneonates with thoracic dystrophy and the need for expert
clinical and radiological assessment of such children.Case presentation
An 11-year-old girl (UPN1) was referred for evaluation
for matched sibling bone marrow transplantation (BMT)
for treatment of MDS. She was the youngest of three
children born to unrelated parents. The first male born
to her parents was small for gestational age, weighing
1.87 kg at term. He had severe chest deformity (baby-
gram shown in Figure 1) and died of respiratory distress
at four hours of age. A diagnosis of probable ATD was
made although no genetic testing could be performed, as
causative genes were unknown at that time. The second
was a well, unaffected male (who subsequently became
the bone marrow donor for UPN1).
Figure 2 Chest radiograph of UPN1 at referral for BMT aged
11 years. There is mild metaphyseal sclerosis and irregularity of the
proximal humeri (black arrows). The posterior ribs are bowed (white
arrows) and there is the impression of cardiomegaly due to the
slightly narrowed thorax.
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vaginal delivery. Her Apgar scores were 6 at one minute
and 8 at 5 minutes and she required suction and oxygen
by mask. Her birth weight was 2.59 kg, length 47 cm and
head circumference 33 cm (all approximately on the 3rd
percentile). From 12 to 36 hours of postnatal life she devel-
oped tachypnoea, reaching a maximum of 120 breaths per
minute. There was no cyanosis. On examination she had
an obvious narrow chest, poor chest expansion, hepato-
megaly of 2 cm and significant tachypnoea but no other
obvious abnormalities. Chest auscultation was clear and
cardiac examination was normal. A chest radiograph (not
available) showed a narrow chest with no evidence of car-
diac disease and the lung fields were consistent with tran-
sient tachypnoea of the neonate. UPN1 was admitted to
the neonatal unit and was discharged 48-hour later with
mild tachypnoea only. A geneticist had reviewed her and a
diagnosis of probable ATD was reached. At this time her
haemoglobin and platelet counts were normal and her
total white cell count was 5.2 x 109/l (no differential per-
formed). Shortly afterwards her respiratory symptoms
resolved completely.
Through the first two years of life head circumference
stayed at the third percentile and her length percentile
dropped. By two years she was 10 cm below the 3rd per-
centile for height and 2 kg below the 3rd percentile for
weight. At 22 months of age she was admitted with sepsis
with a short history of vomiting, pyrexia and a rapidly pro-
gressive purpuric rash. Meningococcal septicaemia was the
presumed diagnosis and she was fully treated for this but
meningococcus was not cultured and coliforms were
grown subsequently from urine. Haemoglobin on admis-
sion was 4.6 g/dl, white cell count was 7.8 x 109/l (neutro-
phils 2.34 x 109/l) and the platelet count was 18 x 109/l.
These abnormalities were presumed to be secondary to se-
vere sepsis and she made a rapid and full response to intra-
venous antibiotics. Ten days later her neutrophils had
dropped to 1.14 x 109/l but platelets had recovered to 53 x
109/l. There is no documented full blood examination until
5 years of age when she developed haemolytic uraemic
syndrome (HUS) and required several weeks of dialysis;
this was followed by intermittent, self-limiting episodes of
haematuria with mild renal impairment. At the time of ad-
mission with HUS she was noted to have learning difficul-
ties and short stature. Renal imaging at the age of 7 years
with ultrasound and DMSA showed no renal scarring,
malformation, dilatation or reflux. At this time and for the
following 4 years her blood counts were normal (including
neutrophils) apart from a platelet count ranging from 43-
161 x 109/l but mostly in the range 50–100 x 109/l.
Between the ages of 9 and 10 years UPN1 progressed to
being consistently pancytopenic (haemoglobin 6.8 g/dl,
white cell count 1.8 x 109/l, neutrophils 0.47 x 109/l, lym-
phocytes 1.09 x 109/l and platelets of 33 x 109/l). She hadno evidence of hepatosplenomegaly or lymphadenopathy.
A bone marrow aspirate and trephine showed normal cel-
lularity with trilineage dysplasia and no fibrosis. There was
no excess of blasts initially, although repeat examination
after referral showed 10% blasts and the marrow had be-
come hypocellular. Cytogenetics revealed a deletion of 7p
in a clone on the initial bone marrow aspirate but serial
testing eventually revealed three different clones, one with
an isochromosome of 7q, an abnormality frequently
described in SDS and rarely seen outside this syndrome
[8]. Lymphocytes showed no increase in chromosome
breakage compared to control in response to mitomycin C
challenge, excluding Fanconi anaemia.
UPN1 became red cell and platelet transfusion
dependent in the year leading up to transplant referral.
During this time she suffered epiglottitis requiring inten-
sive care, a prolonged episode of fever with a perianal
abscess and periorbital cellulitis of one eye. Perianal
soreness and infection became a recurring theme.
Specific questioning to exclude well-recognised causes of
bone marrow failure revealed that UPN1 had passed 1-2
stools per day throughout her life, which were yellow,
offensive and difficult to flush. Microbiological examination
had been consistently negative. Subsequent examination
revealed the presence of fat globules and a reduced faecal
chymotrypsin (0.7U/g, normal range 6-99). Fat-soluble
vitamin levels were reduced (vitamin A 0.6 μmol/l [refer-
ence range 1.1-3.5] and vitamin E 9.7 μmol/l [reference
range 10.2-39.0]). UPN1 was growing but was still small
for age; at eleven years and two months she weighed
22.9 kg (5 kg below 3rd percentile) and was 113 cm tall
(approximately 20 cm below the 3rd percentile). Skeletal
survey (See Figures 2, 3 and 4) revealed abnormalities in
Figure 3 Pelvis radiograph of UPN1 at referral for BMT. There is
prominent sclerosis and lucency in both proximal femoral
metaphyses (black arrow) and femoral necks (white arrow). These
changes extend into the subtrochanteric regions. The acetabular
roofs are horizontal.
Figure 4 Knee radiograph of UPN1. There is sclerosis and lucency
in the distal femoral and proximal tibial metaphyses (white arrows)
with pseudofragmentation of the medial part of the distal femoral
metaphysis (black arrow).
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femoral neck and in the lower femoral and upper tibial
metaphyses. These showed areas of lucency and sclerosis
and irregularity. Coxa valga was present on the right and
some broadening and coxa vara on the left. The ribs were
a little shortened.
The radiographic changes on skeletal survey in com-
bination with the evidence of pancreatic insufficiency,
confirmed a clinical diagnosis of SDS as a cause of her
chondroplasia and bone marrow failure. A DNA sample
from UPN1 was later tested for conversion mutations of
the SBDS gene. The restriction endonuclease digest assay
confirmed mutations c.183_184TA>CT and c.258+2T>C.
These account for 74% of SBDS mutations [9]. Testing of
parental DNA also confirmed that one mutated allele was
inherited from each parent.
UPN1 had significant learning difficulties and was in a
special school. MRI brain was unremarkable. She was
commenced on fat-soluble vitamins and pancreatic en-
zyme replacement with rapid improvement in stool fre-
quency and consistency. An MRI scan of the abdomen
showed that the pancreas was bulky and infiltrated with
fat. At referral she was receiving packed cell transfusions
every three weeks and platelets approximately weekly, but
blood counts improved rapidly following pancreatic and
vitamin supplementation. During the following 16 months,
she required only one further packed cell transfusion and
became platelet independent, although she did require G-
CSF in order to increase her neutrophil count. She had
minimal infectious complications. Due to this improve-
ment, plans for transplantation were postponed.
When UPN1 was 12.5 years old, her blood count fell
further, she developed pyrexia of unknown origin (PUO)
lasting four weeks and was admitted for intravenousantibiotics. During this time her spleen enlarged to
14 cm below the costal margin, causing significant ab-
dominal discomfort. The PUO settled and she was dis-
charged but returned 4 months later with recurrence of
fever and further progression of splenomegaly. Extensive
imaging was performed during these two admissions.
Chest radiographs and CT scans initially showed no
focus of infection. There was hepatosplenomegaly and,
of note, the pancreas was enlarged with markedly
reduced attenuation consistent with being almost com-
pletely replaced by fat (See Figure 5). There was also
mural thickening of the sigmoid colon and rectum, sug-
gesting neutropenic colitis/proctitis as the cause of PUO
(See Figure 6). Lung function studies revealed both FVC
and FEV1 in the low normal range.
Progressive splenomegaly was thought to be related to
progression of MDS and chronic G-CSF exposure as im-
aging showed no evidence of portal hypertension. UPN1
Figure 5 Contrast enhanced computed tomography (CT) of
abdomen. The spleen is enlarged and contains a well-defined
wedge shaped peripheral zone of low attenuation which does not
enhance consistent with infarction (arrows). There is enlargement
and tortuosity of the splenic vein. The pancreas is enlarged and of
uniform low attenuation consistent with fatty replacement.
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tics with no evidence of invasive fungal disease. Splenec-
tomy was performed due to concerns that splenic
sequestration was contributing to decreasing blood counts.
Pathology revealed a large spleen (737 grams compared
with mean weight for age being 89 grams) with several
areas of infarction. The white pulp was atrophic and the
red pulp congested. Microscopy showed areas of infarc-
tion with diffuse expansion of the red pulp, resulting
from extensive infiltration of left shifted myeloid cells
and clusters of atypical blasts. These features were
thought to be attributable to MDS. Rectal biopsy was also
performed, revealing features consistent with neutropenic
colitis.Figure 6 Contrast enhanced computed tomography (CT) of
abdomen. There is wall thickening of the sigmoid colon with
stranding of adjacent mesenteric fat (arrow). The appearances are
of colitis.Persistent neutropenia, abdominal pain and recurrent
fevers necessitated matched sibling BMT after condition-
ing therapy comprising fludarabine (125 mg/m2), melpha-
lan (140 mg/m2) and alemtuzumab (0.9 mg/kg). This
procedure was complicated by primary graft rejection, ne-
cessitating re-transplantation following administration of
fludarabine (100 mg/m2), high dose methylprednisolone
(10 mg/kg twice daily for four doses, then 2 mg/kg twice
daily for four doses followed by slow weaning) and
OKT3 (0.2 mg/kg for eight doses). This was followed by
rapid and uncomplicated donor engraftment. Mixed T-cell
chimerism led to donor lymphocyte infusions to reduce
the risk of relapse of MDS. UPN1 is now over 5 years
post-transplant and is well with normal blood counts.
Whole blood and T-cell chimerism levels are 98% and 89%
donor respectively. Hepatomegaly resolved rapidly follow-
ing successful engraftment.
Conclusions
SDS poses a number of diagnostic challenges when it pre-
sents with severe neonatal respiratory distress. Firstly, al-
though previously described [8], this presentation is rare.
Secondly and very importantly, many of the cardinal
symptoms such as steatorrhoea, failure to thrive and neu-
tropenia may not be apparent soon after birth, or not be
recognised unless the information is specifically sought. As
many SDS patients have improvement in pancreatic func-
tion over time and the neutropenia fluctuates, the diag-
nosis may become more difficult to establish as the
child develops. Thirdly, the characteristic chondrodys-
plasia often seen in this condition may well not become
apparent until the second or third year of life. Thus, a child
with neonatal respiratory distress consequent on severe
thoracic dystrophy is much more likely to be diagnosed
with a primary skeletal dysplasia, such as ATD, than with
SDS. SDS is also largely managed by gastroenterologists
and haematologists, rather than those who would likely
see a neonate in respiratory distress.
There is a further serious source of confusion, as pan-
creatic insufficiency is said to occur in both diseases. It is
a major component of SDS, the pancreatic stimulation
test being abnormal in 100% of cases in the three major
published series of SDS [13-15], and occurs far earlier
than in ATD. The association of pancreatic insufficiency
and ATD is widely cited in articles and textbooks, as well
as on various websites and online resources. However,
the excellent review of ATD by de Vries et al. [2] identi-
fies only two articles which detail this link.
The first, by Karjoo et al. in 1973 [17] described a neo-
natal sibling pair who were thought to have ATD and had
pancreatic insufficiency. However, Danks et al. from 1976
[18], reported two sets of siblings with metaphyseal chon-
drodysplasia, neutropenia and pancreatic insufficiency who
presented in the neonatal period with respiratory distress.
Keogh et al. BMC Pediatrics 2012, 12:48 Page 6 of 7
http://www.biomedcentral.com/1471-2431/12/48One set were the same children described previously by
Karjoo et al. as having ATD. It seems almost certain that
these four children all suffered from SDS, although testing
for the SBDS gene was not available at that time. Unfortu-
nately, modern literature searches do not pick up on the
fact that one of the sibling pairs described by Karjoo was
later realised to have SDS. Therefore, reviews of ATD con-
tinue to associate pancreatic insufficiency with ATD.
The second paper mentioned by de Vries, written by
Turkel et al. [20] from 1985 (again prior to the capacity to
genetically test for SDS) reported the necropsy findings of
seven newborn infants with presumed ATD. In the discus-
sion it states, “pancreatic exocrine insufficiency is a rare
complication seen in older patients with Jeune ATD” and
references only one paper from 1978, which we are unable
to obtain. We believe that it is reasonable to assume that
pancreatic insufficiency is therefore not a feature of ATD
in childhood. Although pathological examination reveals
cystic changes and fibrosis on necropsy, it is unlikely that
these become clinically significant until late in life (if ever).
Thus, if a child with thoracic dystrophy has evidence of
pancreatic insufficiency, we suggest that pancreatic im-
aging, pancreatic function testing and SBDS genotyping
should be performed.
In the case that we have reported here, the initial diag-
nosis was made in an index male sibling whose thoracic
dystrophy was so severe that he died within the first 24
hours of life. Clearly, there would have been nothing on
which to base a potential diagnosis of SDS at that stage.
When his sister was also born with thoracic dystrophy, it
was natural for the clinical team concerned to conclude
that this was a second case of the same disease. A full
blood examination on day two of life was normal al-
though no white cell differential is available from this
time. Blood count abnormalities were evident at
22 months of age but only in the context of severe sepsis.
Neutropenia was not a prominent and consistent feature
until 9 years of age. The subsequent (and still unex-
plained) development of haemolytic uremic syndrome
was thought to be due to ATD, since renal lesions have
been described. This distracted from critical analysis of
other features, such as evolving cytopenia and extra-
thoracic infections, that were inconsistent with the clas-
sical picture of ATD.
Since 2007 several causative genes for forms of ATD
have been described, although in most cases no causative
gene is yet identified. Tests which may contribute to the
exclusion of SDS include measurement of faecal fat,
serum trypsinogen levels, imaging looking for pancreatic
lipomatosis (See Figure 5) and scrutinising the blood
count for neutropenia (defined as the neutrophil count
of less than 1 x 109/l in a child of less than one year of
age) on more than one occasion. Expert review of radi-
ology should be able to distinguish the two conditions ininfancy (personal communication, Professor Christine
Hall). If clear diagnosis is not possible in the neonatal
period we would advise referral to a specialist skeletal
dysplasia service. Unless definitive genetic testing is done
and confirms a diagnosis, we also suggest keeping an
open mind, as diagnostic certainty can be gained with
time.
This case raises a second broader concern, which is
that, once associations have been described, they are eas-
ily perpetuated through internet sites and the medical lit-
erature, even if they are subsequently disproven or
discredited. For example, at the time that we were first
investigating this patient one specialist website on Jeune
syndrome gave a detailed account of a child believed to
have that disease who was neutropenic and on pancreatic
supplements. This patient was subsequently reclassified
as having SDS.
Accurate diagnosis of these children has major implica-
tions for management, prognosis, and counselling of the
affected individuals and their families. We, therefore, ad-
vise expert clinical and radiological review of patients with
neonatal thoracic dystrophy. Where a genetic diagnosis of
ATD is not confirmed, pancreatic lipomatosis and evolving
neutropenia should be excluded.
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